Chemomab and Scipher Merge to Advance RA Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Source: Newsfilter
- Merger Agreement: Chemomab and Scipher have entered into a merger agreement, with the combined entity expected to operate as 'Scipher Medicine Corporation' and trade on Nasdaq, marking a significant advancement in precision medicine.
- Clinical Trial Plans: The merged company plans to initiate a Phase 2 clinical trial for nebokitug targeting rheumatoid arthritis in H1 2028, leveraging Scipher's AI Network Medicine platform to enhance clinical success rates and address the urgent market need for new therapies.
- Funding Support: The merger transaction has secured a commitment of $30 million in financing from investors including Northpond Ventures, with the combined company's cash runway expected to extend into H2 2028, providing ample funding for nebokitug's development.
- Significant Market Potential: As the first antibody targeting CCL24, nebokitug addresses a $24 billion market, and the merger is poised to create substantial value for shareholders, particularly in the context of the current lack of new therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMMB
Wall Street analysts forecast CMMB stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.770
Low
10.00
Averages
17.50
High
25.00
Current: 2.770
Low
10.00
Averages
17.50
High
25.00
About CMMB
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chemomab and Scipher Merge to Advance RA Drug Development
- Merger Agreement: Chemomab and Scipher have entered into a merger agreement, with the combined entity expected to operate as 'Scipher Medicine Corporation' and trade on Nasdaq, marking a significant advancement in precision medicine.
- Clinical Trial Plans: The merged company plans to initiate a Phase 2 clinical trial for nebokitug targeting rheumatoid arthritis in H1 2028, leveraging Scipher's AI Network Medicine platform to enhance clinical success rates and address the urgent market need for new therapies.
- Funding Support: The merger transaction has secured a commitment of $30 million in financing from investors including Northpond Ventures, with the combined company's cash runway expected to extend into H2 2028, providing ample funding for nebokitug's development.
- Significant Market Potential: As the first antibody targeting CCL24, nebokitug addresses a $24 billion market, and the merger is poised to create substantial value for shareholders, particularly in the context of the current lack of new therapies.
See More
Chemomab and Scipher Enter Definitive Merger Agreement
- Merger Agreement: Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement, with the combined entity expected to operate as Scipher Medicine and trade on Nasdaq under the ticker symbol 'SCIP', enhancing their market position in the biopharmaceutical sector.
- Clinical Trial Advancement: The merged company plans to focus on advancing nebokitug, a first-in-class anti-CCL24 antibody, into a Phase 2 trial for rheumatoid arthritis, which, if successful, could provide a new revenue stream for the company.
- Financing Support: To support the merger, a syndicate of existing Scipher investors has committed approximately $30 million in financing for Chemomab and the combined company, ensuring operational funding through the second half of 2028.
- Management Changes: Following the merger, Dr. Reginald Seeto will serve as CEO, while Chemomab co-founder Adi Mor, PhD, will join the board of the combined company, facilitating the integration of leadership to drive strategic objectives.
See More
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Chemomab Therapeutics Reports Q1 Financial Results
- Financial Performance: Chemomab Therapeutics reported a GAAP EPS of $0.00 for Q1 2026, with a net loss of $1.8 million, an improvement from a net loss of $3.3 million in Q1 2025, indicating efforts in cost control.
- Per Share Loss: The net loss per basic and diluted ordinary share for Q1 2026 remained below $0.01, reflecting stable financial performance despite ongoing losses, which may impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $8.0 million in cash, cash equivalents, and short-term bank deposits, down from $10.4 million as of December 31, 2025, highlighting challenges in cash management.
- Funding Outlook: The current cash runway is expected to sustain operations through the end of Q1 2027, indicating a need for careful financial planning to ensure continued operational viability.
See More
Chemomab Therapeutics Reports Q4 Financial Results
- Net Loss Overview: Chemomab Therapeutics reported a net loss of $1.9 million for Q4, translating to less than $0.01 per share, indicating financial strain under ongoing R&D investments that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company held $10.4 million in cash, cash equivalents, and short-term bank deposits, which, while providing some liquidity, necessitates careful management to support ongoing operations and research.
- Financial Transparency: Chemomab Therapeutics has provided detailed financial information, reflecting its commitment to transparency, which could help bolster investor confidence despite the current poor financial performance.
- Market Reaction Outlook: Given the ongoing net losses and limited cash reserves, the market is expected to maintain a cautious stance towards Chemomab's future performance, potentially affecting its stock price and investor sentiment.
See More
Chemomab and Scipher Merge to Advance RA Drug Development
- Merger Agreement: Chemomab and Scipher have entered into a merger agreement, with the combined entity expected to operate as 'Scipher Medicine Corporation' and trade on Nasdaq, marking a significant advancement in precision medicine.
- Clinical Trial Plans: The merged company plans to initiate a Phase 2 clinical trial for nebokitug targeting rheumatoid arthritis in H1 2028, leveraging Scipher's AI Network Medicine platform to enhance clinical success rates and address the urgent market need for new therapies.
- Funding Support: The merger transaction has secured a commitment of $30 million in financing from investors including Northpond Ventures, with the combined company's cash runway expected to extend into H2 2028, providing ample funding for nebokitug's development.
- Significant Market Potential: As the first antibody targeting CCL24, nebokitug addresses a $24 billion market, and the merger is poised to create substantial value for shareholders, particularly in the context of the current lack of new therapies.
See More
Chemomab and Scipher Enter Definitive Merger Agreement
- Merger Agreement: Chemomab Therapeutics and Scipher Medicine have announced a definitive merger agreement, with the combined entity expected to operate as Scipher Medicine and trade on Nasdaq under the ticker symbol 'SCIP', enhancing their market position in the biopharmaceutical sector.
- Clinical Trial Advancement: The merged company plans to focus on advancing nebokitug, a first-in-class anti-CCL24 antibody, into a Phase 2 trial for rheumatoid arthritis, which, if successful, could provide a new revenue stream for the company.
- Financing Support: To support the merger, a syndicate of existing Scipher investors has committed approximately $30 million in financing for Chemomab and the combined company, ensuring operational funding through the second half of 2028.
- Management Changes: Following the merger, Dr. Reginald Seeto will serve as CEO, while Chemomab co-founder Adi Mor, PhD, will join the board of the combined company, facilitating the integration of leadership to drive strategic objectives.
See More
Biotech Companies See Significant Stock Gains
- SL Science Surge: SL Science Holding Limited (SLBT) saw its stock price soar over 50% after its Nasdaq listing, closing at $5.99, reflecting strong market interest in its innovative cellular and gene therapies targeting significant unmet medical needs like pancreatic cancer and glioblastoma.
- Chemomab's Clinical Progress: Chemomab Therapeutics Ltd. (CMMB) experienced a stock increase of over 30%, closing at $2.27, as its lead drug candidate Nebokitug prepares for a Phase 3 trial in primary sclerosing cholangitis, highlighting its potential in treating fibro-inflammatory diseases.
- Propanc's Buyback Initiative: Propanc Biopharma Inc. (PPCB) announced a share repurchase program of up to $500,000, leading to a 22.92% stock increase to $1.77, indicating confidence in its cancer treatment candidate PRP and plans for a first-in-human study in advanced cancer patients.
- Tectonic's Clinical Trial Updates: Tectonic Therapeutic Inc. (TECX) saw its stock rise over 15%, closing at $37.93, as its lead candidates TX45 and TX2100 progress in clinical trials, with significant data expected in late 2026 or early 2027, potentially driving future growth.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Chemomab Therapeutics Reports Q1 Financial Results
- Financial Performance: Chemomab Therapeutics reported a GAAP EPS of $0.00 for Q1 2026, with a net loss of $1.8 million, an improvement from a net loss of $3.3 million in Q1 2025, indicating efforts in cost control.
- Per Share Loss: The net loss per basic and diluted ordinary share for Q1 2026 remained below $0.01, reflecting stable financial performance despite ongoing losses, which may impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $8.0 million in cash, cash equivalents, and short-term bank deposits, down from $10.4 million as of December 31, 2025, highlighting challenges in cash management.
- Funding Outlook: The current cash runway is expected to sustain operations through the end of Q1 2027, indicating a need for careful financial planning to ensure continued operational viability.
See More
Chemomab Therapeutics Reports Q4 Financial Results
- Net Loss Overview: Chemomab Therapeutics reported a net loss of $1.9 million for Q4, translating to less than $0.01 per share, indicating financial strain under ongoing R&D investments that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company held $10.4 million in cash, cash equivalents, and short-term bank deposits, which, while providing some liquidity, necessitates careful management to support ongoing operations and research.
- Financial Transparency: Chemomab Therapeutics has provided detailed financial information, reflecting its commitment to transparency, which could help bolster investor confidence despite the current poor financial performance.
- Market Reaction Outlook: Given the ongoing net losses and limited cash reserves, the market is expected to maintain a cautious stance towards Chemomab's future performance, potentially affecting its stock price and investor sentiment.
See More
